加载页面时好像出了点问题.
我们的团队已经注意到了，但如果问题仍然存在，请使用电子邮件支持小工具联系我们。
| Metrics | Range | Conclusion |
|---|---|---|
| Selected LTM P/E Multiple | -9.4x - -10.4x | -9.9x |
| Selected Fwd P/E Multiple | -10.6x - -11.8x | -11.2x |
| Fair Value | 2.83¥ - 3.13¥ | 2.98¥ |
| Upside | -38.5% - -32.0% | -35.3% |
| Benchmarks | - | Full Ticker |
| Jiangxi Fushine Pharmaceutical Co., Ltd. | 30,049,700.0% | SZSE:300497 |
| Ji Yao Holding Group Co., Ltd. | 30,010,800.0% | SZSE:300108 |
| Hunan Hansen Pharmaceutical Co., Ltd. | 241,200.0% | SZSE:002412 |
| Shandong Sinobioway Biomedicine Co., Ltd. | 258,100.0% | SZSE:002581 |
| Fujian Cosunter Pharmaceutical Co., Ltd. | 30,043,600.0% | SZSE:300436 |
| Hunan Jingfeng Pharmaceutical Co.,Ltd. | 90,800.0% | SZSE:000908 |
| - | - | - |
| Select Price / LTM EPS Ratio | ||||||||
| Benchmark Companies | ||||||||
| 300497 | 300108 | 2412 | 2581 | 300436 | 908 | |||
| SZSE:300497 | SZSE:300108 | SZSE:002412 | SZSE:002581 | SZSE:300436 | SZSE:000908 | |||
| Historical Net Income Growth | ||||||||
| 5Y CAGR | NM- | NM- | 6.8% | NM- | NM- | NM- | ||
| 3Y CAGR | NM- | NM- | 24.5% | NM- | NM- | NM- | ||
| Latest Twelve Months | 32.6% | -289.6% | 53.5% | -603.3% | 11.3% | -122.4% | ||
| Historical Net Income Profit Margin | ||||||||
| 5 Year Average Margin | 2.5% | -112.3% | 17.8% | -11.4% | -27.5% | -66.7% | ||
| Prior Fiscal Year | -8.6% | -56.4% | 18.3% | -4.1% | -33.0% | -14.6% | ||
| Latest Fiscal Year | -12.5% | -100.9% | 21.5% | -77.4% | -82.5% | -32.8% | ||
| Latest Twelve Months | -13.9% | -120.3% | 23.4% | -85.6% | -47.6% | -71.9% | ||
| Current Trading Multiples | ||||||||
| EV / LTM EBITDA | 857.9x | -10.6x | 7.1x | -128.5x | -233.0x | -39.8x | ||
| Price / LTM Sales | 3.3x | 1.8x | 3.3x | 15.9x | 11.0x | 10.0x | ||
| LTM P/E Ratio | -24.0x | -1.5x | 14.0x | -18.6x | -23.2x | -13.8x | ||
| Low | Mid | High | ||||||
| Benchmark LTM P/E Ratio | -24.0x | -18.6x | 14.0x | |||||
| Historical LTM P/E Ratio | -45.8x | -13.5x | -3.4x | |||||
| Selected P/E Multiple | -9.4x | -9.9x | -10.4x | |||||
| (x) LTM Net Income | (286) | (286) | (286) | |||||
| (=) Equity Value | 2,689 | 2,831 | 2,973 | |||||
| (/) Shares Outstanding | 879.8 | 879.8 | 879.8 | |||||
| Implied Value Range | 3.06 | 3.22 | 3.38 | |||||
| FX Rate: CNY/CNY | 1.0 | 1.0 | 1.0 | Market Price | ||||
| Implied Value Range (Trading Cur) | 3.06 | 3.22 | 3.38 | 4.60 | ||||
| Upside / (Downside) | -33.5% | -30.0% | -26.5% | |||||
| Equity Value | |||||||
| Benchmark Companies | |||||||
| (in millions) | 300497 | 300108 | 2412 | 2581 | 300436 | 908 | |
| Value of Common Equity | 4,331 | 659 | 3,170 | 6,439 | 5,144 | 4,047 | |
| (/) Shares Outstanding | 538.6 | 666.0 | 503.2 | 659.7 | 159.3 | 879.8 | |
| Implied Stock Price | 8.04 | 0.99 | 6.30 | 9.76 | 32.30 | 4.60 | |
| FX Conversion Rate to Trading Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | |
| Implied Stock Price (Trading Cur) | 8.04 | 0.99 | 6.30 | 9.76 | 32.30 | 4.60 | |
| Trading Currency | CNY | CNY | CNY | CNY | CNY | CNY | |
| FX Rate to Reporting Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | |